A medicinal agent for the prevention and/or treatment of diseases caused by EP.sub.4 receptor activation. A compound having antagonistic activity against the EP.sub.4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP.sub.4 receptor for the prevention and/or treatment of diseases caused by EP.sub.4 receptor activation.

##STR00001##

The present invention relates to a novel anthracene derivative, for an organic light-emitting device, and an organic light-emitting device comprising same, the anthracene derivative enabling excellent device characteristics when used as a light-emitting material.

The present invention relates to a novel anthracene derivative, for an organic light-emitting device, and an organic light-emitting device comprising same, the anthracene derivative enabling excellent device characteristics when used as a light-emitting material.

The present disclosure relates to an organic light-emitting diode having a low driving voltage and long lifespan and more particularly, to an organic light-emitting diode, comprising a first electrode, a second electrode facing the first electrode, and a light-emitting layer interposed therebetween, wherein the light-emitting layer contains at least one of the amine compounds represented by the following Chemical Formula A or Chemical Formula B, plus the compound represented by Chemical Formula D. The structures of Chemical Formulas A, B, and D are the same as in the specification.

The present disclosure relates to an organic light-emitting diode having a low driving voltage and long lifespan and more particularly, to an organic light-emitting diode, comprising a first electrode, a second electrode facing the first electrode, and a light-emitting layer interposed therebetween, wherein the light-emitting layer contains at least one of the amine compounds represented by the following Chemical Formula A or Chemical Formula B, plus the compound represented by Chemical Formula D. The structures of Chemical Formulas A, B, and D are the same as in the specification.

CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compound or salt. The present invention also provides a drug for the prevention or treatment of diseases associated with the activation of TLR7, said drug including the aforementioned TLR7 activation inhibitor.

CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compound or salt. The present invention also provides a drug for the prevention or treatment of diseases associated with the activation of TLR7, said drug including the aforementioned TLR7 activation inhibitor.

The present invention relates to novel spirobicyclic analogues of Formula (I) ##STR00001##
wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

The present disclosure relates to an organic compound. The structure of the organic compound consists of a structure represented by formula (I) and a structure represented by formula (II); the structure represented by formula (I) is fused with the structure represented by formula (II); and * represents a connection point, in formula (I), capable of being fused with formula (II). When being used to the organic light-emitting layer of an organic electroluminescent device, the organic compound of the present application can effectively improve the device efficiency of the device and prolong the service life of the organic electroluminescent device.

##STR00001##

The present disclosure relates to an organic compound. The structure of the organic compound consists of a structure represented by formula (I) and a structure represented by formula (II); the structure represented by formula (I) is fused with the structure represented by formula (II); and * represents a connection point, in formula (I), capable of being fused with formula (II). When being used to the organic light-emitting layer of an organic electroluminescent device, the organic compound of the present application can effectively improve the device efficiency of the device and prolong the service life of the organic electroluminescent device.

##STR00001##